BMS buys Mirati for $4.8B; Pfizer to slash cost; Q&A with Vertex CSO; Alnylam’s Onpattro setback; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

After Mirati…
Click here to view original post